Zhang W, Zheng X, Coghi P, Chen J, Dong B, Fan X
Front Immunol. 2024; 15:1438030.
PMID: 39206192
PMC: 11349682.
DOI: 10.3389/fimmu.2024.1438030.
Inci T, Acar S, Turgut-Balik D
Turk J Biol. 2024; 48(2):112-132.
PMID: 39051063
PMC: 11265851.
DOI: 10.55730/1300-0152.2687.
Kim K, Park J, Lee S, Kim H, Kim Y
Korean Circ J. 2023; 53(12):795-810.
PMID: 37880871
PMC: 10751183.
DOI: 10.4070/kcj.2023.0042.
Zhang Y, Zhang Y, Chen C, Cheng H, Deng X, Li D
BMC Microbiol. 2022; 22(1):114.
PMID: 35473561
PMC: 9040290.
DOI: 10.1186/s12866-022-02535-9.
Hiasa M, Harada T, Tanaka E, Abe M
Jpn Dent Sci Rev. 2021; 57:164-173.
PMID: 34611468
PMC: 8477206.
DOI: 10.1016/j.jdsr.2021.08.006.
SANE: A sequence combined attentive network embedding model for COVID-19 drug repositioning.
Su X, You Z, Wang L, Hu L, Wong L, Ji B
Appl Soft Comput. 2021; 111:107831.
PMID: 34456656
PMC: 8381638.
DOI: 10.1016/j.asoc.2021.107831.
Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?.
Campesi I, Racagni G, Franconi F
Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451827
PMC: 8402096.
DOI: 10.3390/ph14080730.
Drug repositioning: a brief overview.
Jourdan J, Bureau R, Rochais C, Dallemagne P
J Pharm Pharmacol. 2020; 72(9):1145-1151.
PMID: 32301512
PMC: 7262062.
DOI: 10.1111/jphp.13273.
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H, Chen X, Li K, Cheaito H, Yang Q, Wu G
Semin Cancer Biol. 2019; 68:105-122.
PMID: 31883910
PMC: 7316602.
DOI: 10.1016/j.semcancer.2019.12.013.
Multiple Myeloma: What Do We Do About Immunodeficiency?.
Li L, Wang L
J Cancer. 2019; 10(7):1675-1684.
PMID: 31205523
PMC: 6548011.
DOI: 10.7150/jca.29993.
Thalidomide decreases high glucose-induced extracellular matrix protein synthesis in mesangial cells via the AMPK pathway.
Zhang H, Yuan J, Li Y, Li R
Exp Ther Med. 2019; 17(1):927-934.
PMID: 30651882
PMC: 6307482.
DOI: 10.3892/etm.2018.6995.
Crystal structure of the thalidomide analog (3a*,7a*)-2-(2,6-dioxopiperidin-3-yl)hexa-hydro-1-iso-indole-1,3(2)-dione.
Hijji Y, Benjamin E, Jasinski J, Butcher R
Acta Crystallogr E Crystallogr Commun. 2018; 74(Pt 11):1595-1598.
PMID: 30443388
PMC: 6218906.
DOI: 10.1107/S2056989018014317.
The effects of thalidomide in a rat model of surgically-induced endometriosis.
Bakacak M, Ercan O, Kostu B, Bostanci M, Inanc F, Yaylali A
Turk J Obstet Gynecol. 2017; 12(3):125-131.
PMID: 28913056
PMC: 5558385.
DOI: 10.4274/tjod.71601.
Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I, Wang H, Caldwell J, Chopra R
Biochem J. 2017; 474(7):1127-1147.
PMID: 28298557
PMC: 5350610.
DOI: 10.1042/BCJ20160762.
Computational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction Prediction.
Coelho E, Arrais J, Oliveira J
PLoS Comput Biol. 2016; 12(11):e1005219.
PMID: 27893735
PMC: 5125559.
DOI: 10.1371/journal.pcbi.1005219.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro J, Buque A, Senovilla L, Baracco E
Oncotarget. 2014; 5(24):12472-508.
PMID: 25537519
PMC: 4350348.
DOI: 10.18632/oncotarget.2998.
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.
Kim D, Nam T, Choe K, Choy H
Cancer Res Treat. 2012; 44(2):74-84.
PMID: 22802745
PMC: 3394867.
DOI: 10.4143/crt.2012.44.2.74.
Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.
Ria R, Reale A, Solimando A, Mangialardi G, Moschetta M, Gelao L
Stem Cells Int. 2012; 2012:607260.
PMID: 22701493
PMC: 3369512.
DOI: 10.1155/2012/607260.
Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma.
Kang M, Ju J, Kim H, Kang J, Jeon K, Kim H
Korean J Intern Med. 2010; 25(4):447-9.
PMID: 21179284
PMC: 2997975.
DOI: 10.3904/kjim.2010.25.4.447.
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintas-Cardama A, Kantarjian H, Manshouri T, Thomas D, Cortes J, Ravandi F
J Clin Oncol. 2009; 27(28):4760-6.
PMID: 19720904
PMC: 4879697.
DOI: 10.1200/JCO.2009.22.6548.
